Barclays raised the firm’s price target on Blueprint Medicines to $70 from $58 and keeps an Equal Weight rating on the shares. The analyst rebuilt the company’s model around the mast cell program and removed lung cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BPMC:
- BPMC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Blueprint Medicines price target raised to $90 from $85 at Oppenheimer
- Blueprint Medicines price target raised to $78 from $58 at Piper Sandler
- Blueprint Medicines says AYVAKIT has potential to be multibillion-dollar therapy
- Blueprint Medicines price target raised to $114 from $89 at Goldman Sachs
